SEC Watching Press Releases, Wants Context For “Preliminary” Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug companies should also fully disclose their role in developing the drug being discussed and accurately describe the drug’s stage of development, SEC tells FDLI conference. FDA says there is “no conspiracy” to increase role in investor communications oversight.
You may also be interested in...
FDA Develops Formal Procedure To Refer Misleading Communications To SEC
Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison between the agencies. FDA will provide "blanket" authorization to certain staff to share non-public information with SEC.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.